Brought to you by 
Janssen's Crucell Holland gets license to Ebola vaccine candidate from Bavarian Nordic
15 Jun 2020
Executive Summary
Danish vaccines firm Bavarian Nordic AS licensed Janssen Pharmaceutical Cos.’s Crucell Holland BV exclusive worldwide rights to its multivalent MVA-BN Filovirus vaccine candidate for the Zaire and Sudan strains of Ebola and the related condition Marburg disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen's Crucell Holland gets license to Ebola vaccine candidate from Bavarian Nordic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice